Acadia Pharmaceuticals Inc (ACAD) Com Stk USD0.0001

Sell:$17.17Buy:$17.19$0.03 (0.17%)

NASDAQ:0.18%
Market closed | Prices delayed by at least 15 minutes
Sell:$17.17
Buy:$17.19
Change:$0.03 (0.17%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$17.17
Buy:$17.19
Change:$0.03 (0.17%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Key people

Catherine Owen Adams
Chief Executive Officer, Director
Mark C. Schneyer
Chief Financial Officer, Executive Vice President
Jennifer J. Rhodes
Executive Vice President, Company Secretary and Chief Legal Officer
Elizabeth H. Z. Thompson
Executive Vice President and Head of Research and Development
Albert Kildani
Senior Vice President, Investor Relations and Corporate Communications
Kevin R. Oliver
Senior Vice President, Chief Business Officer
Holly Valdiviez
Senior Vice President - Neuropsychiatric Franchise
Thomas Andrew Garner
Chief Commercial Officer
Stephen R. Biggar
Independent Chairman of the Board
Julian C. Baker
Independent Director
Laura A. Brege
Independent Director
James Michael Daly
Independent Director
Elizabeth A. Garofalo
Independent Director
Click to see more

Key facts

  • EPIC
    ACAD
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0042251084
  • Market cap
    $2.93bn
  • Employees
    653
  • Shares in issue
    166.79m
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.